Crohn's disease: open trials in Switzerland

12 open trials have a site in Switzerland. Registry data; only the trial team decides who can take part.

NCT07196722
A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease
Trial Treatment · Phase 2/3 · Janssen Research & Development, LLC
Inselspital Universitätsspital Bern, Bern · Kantonsspital Sankt Gallen, Sankt Gallen
Registry updated 2026-11-03
NCT07577843
A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease
Trial Treatment · Phase 3 · Janssen Research & Development, LLC
Gastroenterologische Praxis und Crohn-Collitis Zentrum Bern, Bern · Kantonsspital St Gallen, Saint Ursen
Registry updated 2026-11-03
NCT06233461
A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease
Trial Treatment · Phase 2 · Takeda
University Hospital Basel, Basel · Intesto - Gastroenterologische Praxis & Crohn-Colitis-Zentrum Bern, Bern
Registry updated 2026-11-02
NCT06430801
A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
Trial Treatment · Phase 3 · Merck Sharp & Dohme LLC
University Hospital Basel-Gastroenterology and Hepatology (Site 2204), Basel · INTESTO-Gastroenterologische Praxis / Crohn-Colitis Zentrum Bern (Site 2202), Bern · Cantonal Hospital St.Gallen-Klinik für Gastroenterologie / Hepatologie (Site 2201), Sankt Gallen · UniversitätsSpital Zürich-Gastroenterologie & Hepatologie (Site 2200), Zurich
Registry updated 2026-11-02
NCT07184931
An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
Trial Treatment · Phase 3 · Sanofi
Basel · Bern
Registry updated 2026-10-21
NCT07184944
A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
Trial Treatment · Phase 3 · Sanofi
Basel · Bern
Registry updated 2026-10-21
NCT05995353
A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's Disease
Trial Treatment · Phase 3 · AbbVie
Inselspital, Universitaetsspital Bern /ID# 255321, Bern · Kinderspital Zurich - Eleonorenstiftung /ID# 255337, Zurich
Registry updated 2026-10-20
NCT06405087
A Long-Term Extension Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis (UC) or Crohn's Disease (CD)
Trial Treatment · Phase 3 · Takeda
University Hospital of Bern, Bern · Centre Hospitalier Universitaire Vaudois, Lausanne · University Children's Hospital Zurich, Zurich
Registry updated 2026-10-09
NCT06548542
Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease
Trial Treatment · Phase 2 · AbbVie
Intesto /ID# 265728, Bern · Inselspital, Universitaetsspital Bern /ID# 265733, Bern · University Hospital Zurich /ID# 275755, Zurich
Registry updated 2026-09-25
NCT06100289
A Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Crohn's Disease
Trial Treatment · Phase 3 · Takeda
Inselspital, Universitatsspital Bern, Kinderklinik, Julie-von-Jenner-Haus, Bern · Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne · Universitats-Kinderspital, Zurich
Registry updated 2026-08-03
NCT07532213
A Study to Assess Real-world Outcomes for Long-Term Use of Guselkumab
Research · Janssen-Cilag A.G., Switzerland
Gastroenterologische Praxis und Crohn-Collitis Zentrum Bern, Bern
Registry updated 2026-06-12
NCT06227910
A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease
Trial Treatment · Phase 3 · Takeda
University Hospital Basel, Basel · University Hospital Bern / Inselspital, Bern · Universitätsspital Zürich, Zurich · Zentrum fur Gastroenterologie, Zurich
Registry updated 2026-05-27

All Crohn's disease trials and the map

This page is not medical advice. Talk to your doctor before contacting a trial.

Report an error